Tolerx, Inc.
http://www.tolerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tolerx, Inc.
2023-2024 Global Biopharma R&D Productivity And Growth Ranking
The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
Fabhalta IgAN Nod Plays Into Novartis’s Long-Term Nephrology Development Plan
US FDA approval in IgAN is just the first step in a much larger renal disease strategy for the company, which includes additional kidney indications for Fabhalta.
One In Five English HTAs Terminated Due To Company Non-Submissions And Withdrawals
Since 2019, 91 health technology assessments have been terminated by England’s NICE because companies withdrew their applications or did not submit evidence. In the first of this three-part article series, pharma firms share their reasons for opting out of the process.
Finance Watch: VC Mega-Rounds Ease Into Summer Slowdown
Private Company Edition: Venture capital investment has moved into a slower summer pace, or maybe just shifted to small- and medium-sized biopharma financings. In addition to Third Arc’s $165m series A round, Brenig raised a $65m series A and Confo’s series B totaled €60m ($65m).
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice